NOVOCURE LTD (NVCR)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NVCR
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NVCR | Former President and Chief Operating Officer, Stryker Corporation | 61 | [] | ["Audit"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MASI | Independent Director | ["Over 30 years of experience in delivering market-leading results at Stryker Corporation", "Served as President and Chief Operating Officer of Stryker from 2018 to 2021", "Group President for Stryker\u2019s MedSurg & Neurotechnology businesses for ten years", "Various leadership roles at Stryker including General Manager and Vice President", "Holds a bachelor\u2019s degree in Business Administration and Marketing and an M.B.A from the University of Notre Dame", "Deep Medical Device and Operational experience", "Serves on the boards of several private companies including Regenity Biosciences, Synaptive Medical, and CereVasc, Inc.", "Current board member at Novocure Limited (2021\u2013present) and Insulet Corporation (2014\u2013present)", "Prior board service at EXACT Sciences Corp., Molekule Group, Inc., and Renalytix Plc"] | ["Compensation", "Business Risk & Review"] | 2025 |
Biography sourced from the proxy statement filing.
Mr. Scannell was elected to our Board in February 2021. He recently retired after 32 years of service at Stryker Corporation. At Stryker, Mr. Scannell served as President and Chief Operating Officer from 2018 to 2021. Prior to this position, he served as group president of MedSurg and Neurotechnology from 2008 to 2018 and previously served as vice president/general manager of Stryker Biotech and president of Stryker Spine. Education: University of Notre Dame, B.A. and M.B.A. in Business Administration. Other Public Company Directorships: Director since 2014 and Chairman of the Board from 2019 to 2026 of Insulet Corporation. Formerly a director of Renalytix plc from 2022 to 2023, of Molekule, Inc. from 2022 to 2024, of Exact Sciences Corporation from 2023 to 2024 and of Masimo Corporation from 2024 to 2026. We believe Mr. Scannell is qualified to serve on our Board due to his extensive business experience in our industry and as an executive leading a high-growth med-tech public company.